SYGNIS AG: – Sygnis obtains finance to close the acquisition of the Australian TGR Biosciences PTY LTD –

SYGNIS AG / Key word(s): Financing/Acquisition
SYGNIS AG: – Sygnis obtains finance to close the acquisition of the Australian TGR Biosciences PTY LTD –

02-May-2018 / 16:41 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Heidelberg, Germany and Cambridge, UK, 2 May 2018 – SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard), today announces that it has obtained debt finance to complete the acquisition of the Australian TGR Biosciences PTY LTD. As announced the completion of the transaction was dependent thereon.

SYGNIS has the right to exchange the debt finance (interest and repayment include variable elements) into a mandatory convertible bond with additional option rights for approx. 1.4 mio shares. The volume of the convertible bond and the conversion price will depend upon market conditions at the time SYGNIS exercises such right if SYGNIS decides to do so, which is likely.

Contact:
David Roth
Vorstand/ CFO

SYGNIS AG

Waldhofer Str. 102
69123 Heidelberg, GERMANY

Tel. +49 6221 3540 125
Fax. +49 6221 3540 127


02-May-2018 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


show this